What is the impact to the treatment landscape from the early benefits seen in the EMPEROR trials?
Featuring
Professor Andrew Coats | Australia
Related content
Document ID: PC-MY-102948
Andrew Coats (Australia)
What is the impact of SGLT2 inhibitor trials in HFpEF?
Heart Failure 360: Early protection for every heart failure patient
02:00:53
PRIME Summit 2 : Post event video day 2
02:13:04
PRIME Summit 2 : Post event video day 1
Christiane Angermann (Germany) | Ricardo Carvalho (Portugal)